Načítá se...
Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-A(xxx)b) in colorectal cancer patients predicts tumour VEGF-A ratios
Purpose: Bevacizumab as an adjunct to chemotherapy improves survival for some patients with metastatic colorectal cancer. Immunohistochemical staining of samples from the registration ECOG E3200 trial of bevacizumab with FOLFOX demonstrated that only patients with carcinomas expressing low levels of...
Uloženo v:
| Vydáno v: | Am J Cancer Res |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
e-Century Publishing Corporation
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4529627/ https://ncbi.nlm.nih.gov/pubmed/26269767 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|